Applied Therapeutics (APLT) presented full 12-month clinical results and new topline data from 18 and 24 months from the INSPIRE Phase 2/3 trial of govorestat for the treatment of Sorbitol ...

Applied Therapeutics’ rare disease drug has failed another late-stage clinical trial, adding to the woes of a candidate that ...

The INSPIRE Phase 3 trial was a double-blind, placebo-controlled registrational trial to evaluate the effect of govorestat in patients with Sorbitol Dehydrogenase (SORD) Deficiency, a subtype of ...

along with new topline data from 18 and 24 months from the INSPIRE Phase 3 trial of its drug govorestat for Charcot-Marie-Tooth Sorbitol Dehydrogenase (CMT-SORD) deficiency at the Peripheral Nerve ...

Recent Highlights Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 3 Trial of Govorestat in SORD Deficiency to be Presented at the Peripheral Nerve Society (PNS) 2025 Annual ...

being developed for the treatment of multiple rare diseases including Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD), Classic Galactosemia, and phosphomannomutase 2 congenital ...

The INSPIRE Phase 3 trial was a double-blind, placebo-controlled registrational trial to evaluate the effect of govorestat in patients with Sorbitol Dehydrogenase (SORD) Deficiency, a subtype of ...